These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 23406558)

  • 1. Chemotherapy regimens in early breast cancer: major controversies and future outlook.
    Joerger M; Thürlimann B
    Expert Rev Anticancer Ther; 2013 Feb; 13(2):165-78. PubMed ID: 23406558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multifactorial approach to predicting resistance to anthracyclines.
    Desmedt C; Di Leo A; de Azambuja E; Larsimont D; Haibe-Kains B; Selleslags J; Delaloge S; Duhem C; Kains JP; Carly B; Maerevoet M; Vindevoghel A; Rouas G; Lallemand F; Durbecq V; Cardoso F; Salgado R; Rovere R; Bontempi G; Michiels S; Buyse M; Nogaret JM; Qi Y; Symmans F; Pusztai L; D'Hondt V; Piccart-Gebhart M; Sotiriou C
    J Clin Oncol; 2011 Apr; 29(12):1578-86. PubMed ID: 21422418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor topoisomerase II alpha status and response to anthracycline-based neoadjuvant chemotherapy in breast cancer.
    Nikolényi A; Sükösd F; Kaizer L; Csörgo E; Vörös A; Uhercsák G; Ormándi K; Lázár G; Thurzó L; Brodowicz T; Kahán Z
    Oncology; 2011; 80(3-4):269-77. PubMed ID: 21734419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic potential of topoisomerase IIα and HER2 in a retrospective analysis of early advanced breast cancer patients treated with adjuvant anthracycline chemotherapy.
    Biesaga B; Niemiec J; Ziobro M; Wysocka J; Kruczak A
    Breast; 2011 Aug; 20(4):338-50. PubMed ID: 21507646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of topoisomerase IIα in predicting sensitivity to anthracyclines in breast cancer patients: a meta-analysis of published literatures.
    Du Y; Zhou Q; Yin W; Zhou L; Di G; Shen Z; Shao Z; Lu J
    Breast Cancer Res Treat; 2011 Oct; 129(3):839-48. PubMed ID: 21809115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validity of the proliferation markers Ki67, TOP2A, and RacGAP1 in molecular subgroups of breast cancer.
    Milde-Langosch K; Karn T; Müller V; Witzel I; Rody A; Schmidt M; Wirtz RM
    Breast Cancer Res Treat; 2013 Jan; 137(1):57-67. PubMed ID: 23135572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Predictive factors for response to chemotherapy in breast cancers].
    Miyoshi Y; Noguchi S
    Nihon Rinsho; 2007 Jun; 65 Suppl 6():154-9. PubMed ID: 17682152
    [No Abstract]   [Full Text] [Related]  

  • 8. Optimizing the use of anthracyclines in older patients with breast cancer.
    Morris PG; Fornier MN
    Crit Rev Oncol Hematol; 2011 Feb; 77(2):131-41. PubMed ID: 20227291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial.
    Skarlos P; Christodoulou C; Kalogeras KT; Eleftheraki AG; Bobos M; Batistatou A; Valavanis C; Tzaida O; Timotheadou E; Kronenwett R; Wirtz RM; Kostopoulos I; Televantou D; Koutselini E; Papaspirou I; Papadimitriou CA; Pectasides D; Gogas H; Aravantinos G; Pavlidis N; Arapantoni P; Skarlos DV; Fountzilas G
    Cancer Chemother Pharmacol; 2012 Feb; 69(2):533-46. PubMed ID: 21901395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant therapy for HER2 positive breast cancer: are anthracyclines still necessary?
    Castrellon AB; Glück S
    Clin Adv Hematol Oncol; 2008 Sep; 6(9):666-72. PubMed ID: 18827789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of anthracyclines in the treatment of early breast cancer.
    Greene J; Hennessy B
    J Oncol Pharm Pract; 2015 Jun; 21(3):201-12. PubMed ID: 24769570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distribution of podoplanin-positive tumor vessels predicts disease-specific survival of node-positive breast cancer patients treated with anthracyclines and/or taxanes.
    Niemiec JA; Adamczyk A; Ambicka A; Mucha-Małecka A; Wysocki WM; Ryś J
    Cancer Invest; 2014 Jun; 32(5):168-77. PubMed ID: 24605901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is anthracycline-based chemotherapy alone adequate for young women with estrogen receptor-positive breast cancer?
    Papaldo P; Di Cosimo S; Ferretti G; Carlini P; Fabi A; Cecere F; Cognetti F
    Breast; 2006 Apr; 15(2):269-72. PubMed ID: 16131469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metastatic breast cancer with liver metastases: a registry analysis of clinicopathologic, management and outcome characteristics of 500 women.
    Pentheroudakis G; Fountzilas G; Bafaloukos D; Koutsoukou V; Pectasides D; Skarlos D; Samantas E; Kalofonos HP; Gogas H; Pavlidis N
    Breast Cancer Res Treat; 2006 Jun; 97(3):237-44. PubMed ID: 16322882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Topoisomerase II alpha expression and the Ki-67 labeling index correlate with prognostic factors in estrogen receptor-positive and human epidermal growth factor type-2-negative breast cancer.
    Tokiniwa H; Horiguchi J; Takata D; Kikuchi M; Rokutanda N; Nagaoka R; Sato A; Odawara H; Tozuka K; Oyama T; Takeyoshi I
    Breast Cancer; 2012 Oct; 19(4):309-14. PubMed ID: 21725655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hormone receptor-positive early breast cancer: controversies in the use of adjuvant chemotherapy.
    Montemurro F; Aglietta M
    Endocr Relat Cancer; 2009 Dec; 16(4):1091-102. PubMed ID: 19726539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401.
    ; Tanner M; Isola J; Wiklund T; Erikstein B; Kellokumpu-Lehtinen P; Malmström P; Wilking N; Nilsson J; Bergh J
    J Clin Oncol; 2006 Jun; 24(16):2428-36. PubMed ID: 16682728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Different prognostic significance of Ki-67 change between pre- and post-neoadjuvant chemotherapy in various subtypes of breast cancer.
    Matsubara N; Mukai H; Fujii S; Wada N
    Breast Cancer Res Treat; 2013 Jan; 137(1):203-12. PubMed ID: 23184081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Topoisomerase IIalpha gene status and prediction of pathological complete remission after anthracycline-based neoadjuvant chemotherapy in endocrine non-responsive Her2/neu-positive breast cancer.
    Orlando L; Del Curto B; Gandini S; Ghisini R; Pietri E; Torrisi R; Balduzzi A; Cardillo A; Dellapasqua S; Veronesi P; Viale G; Goldhirsch A; Colleoni M
    Breast; 2008 Oct; 17(5):506-11. PubMed ID: 18456496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene expression profiling of breast cancer patients treated with docetaxel, doxorubicin, and cyclophosphamide within the GEPARTRIO trial: HER-2, but not topoisomerase II alpha and microtubule-associated protein tau, is highly predictive of tumor response.
    Rody A; Karn T; Gätje R; Ahr A; Solbach C; Kourtis K; Munnes M; Loibl S; Kissler S; Ruckhäberle E; Holtrich U; von Minckwitz G; Kaufmann M
    Breast; 2007 Feb; 16(1):86-93. PubMed ID: 17010609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.